EA027986B9 - Соединения триазолона и их применение - Google Patents

Соединения триазолона и их применение

Info

Publication number
EA027986B9
EA027986B9 EA201590909A EA201590909A EA027986B9 EA 027986 B9 EA027986 B9 EA 027986B9 EA 201590909 A EA201590909 A EA 201590909A EA 201590909 A EA201590909 A EA 201590909A EA 027986 B9 EA027986 B9 EA 027986B9
Authority
EA
Eurasian Patent Office
Prior art keywords
melanoma
pancreatic
cancers
colon
breast
Prior art date
Application number
EA201590909A
Other languages
English (en)
Other versions
EA201590909A1 (ru
EA027986B1 (ru
Inventor
Николас Саймон Сток
Остин Чи-Ю Чен
Ялда Мостофи Браво
Джейсон Дуарте Джасинто
Джилл Мелисса Баккей
Брайан Эндрю Стирнс
Райан Кристофер Кларк
Original Assignee
Инсепшн 2, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Инсепшн 2, Инк. filed Critical Инсепшн 2, Инк.
Publication of EA201590909A1 publication Critical patent/EA201590909A1/ru
Publication of EA027986B1 publication Critical patent/EA027986B1/ru
Publication of EA027986B9 publication Critical patent/EA027986B9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретение относится к соединениям формулы Iи их фармацевтически приемлемым солям, которые пригодны для лечения рака предстательной железы, молочной железы, толстой кишки, поджелудочной железы, хронического лимфоцитарного лейкоза человека, меланомы и других видов рака. Изобретение также включает фармацевтические композиции, содержащие терапевтически эффективное количество соединения формулы I или его фармацевтически приемлемой соли. Изобретение также относится к способам лечения рака предстательной железы, молочной железы, яичников, печени, почек, толстой кишки, поджелудочной железы, хронического лимфоцитарного лейкоза человека, меланомы и других видов рака. Изобретение также относится к способам лечения рака предстательной железы, молочной железы, толстой кишки, поджелудочной железы, хронического лимфоцитарного лейкоза, меланомы и других видов рака, включающим введение терапевтически эффективного количества селективного антагониста РАПП-α. Соединения и фармацевтические композиции согласно настоящему изобретению также пригодны для лечения вирусных инфекций, таких как ВГС-инфекции и ВИЧ-инфекции.
EA201590909A 2012-12-20 2013-12-10 Соединения триазолона и их применение EA027986B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261739906P 2012-12-20 2012-12-20
PCT/US2013/074197 WO2014099503A1 (en) 2012-12-20 2013-12-10 Triazolone compounds and uses thereof

Publications (3)

Publication Number Publication Date
EA201590909A1 EA201590909A1 (ru) 2015-12-30
EA027986B1 EA027986B1 (ru) 2017-09-29
EA027986B9 true EA027986B9 (ru) 2018-01-31

Family

ID=50979036

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590909A EA027986B9 (ru) 2012-12-20 2013-12-10 Соединения триазолона и их применение

Country Status (17)

Country Link
US (4) US9676754B2 (ru)
EP (1) EP2935228B9 (ru)
JP (1) JP6404230B2 (ru)
KR (1) KR102300675B1 (ru)
CN (1) CN104918922B (ru)
AU (1) AU2013363398B2 (ru)
BR (1) BR112015013350B1 (ru)
CA (1) CA2894281C (ru)
DK (1) DK2935228T3 (ru)
EA (1) EA027986B9 (ru)
ES (1) ES2660249T3 (ru)
IL (1) IL239372B (ru)
MX (1) MX376108B (ru)
NO (1) NO3003327T3 (ru)
PE (1) PE20151521A1 (ru)
SG (1) SG11201504622PA (ru)
WO (1) WO2014099503A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201504622PA (en) 2012-12-20 2015-07-30 Inception 2 Inc Triazolone compounds and uses thereof
CN105579440A (zh) 2013-09-06 2016-05-11 因森普深2公司 三唑酮化合物及其应用
WO2022052982A1 (zh) * 2020-09-14 2022-03-17 昭明泽康（北京）生物医药科技有限公司 PPARα（过氧化物酶体增殖物激活受体α）配体在制备药物中的应用
CN114853686B (zh) * 2021-08-23 2023-06-20 中国药科大学 三氮唑酮类化合物及其医药用途
TW202428262A (zh) * 2022-11-09 2024-07-16 美商坦帕斯醫療公司 三唑酮化合物及其用途
WO2025235527A1 (en) 2024-05-08 2025-11-13 Tempest Therapeutics, Inc. Crystalline forms of a ppar alpha antagonist

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE160447C (ru)
DK160611C (da) 1979-09-04 1991-09-16 Bristol Myers Squibb Co Analogifremgangsmaade til fremstilling af 3,4-disubstituerede 1,2,5-thiadiazol-1-oxider og -1,1-dioxider
US4487773A (en) 1981-03-16 1984-12-11 Mead Johnson & Company 1,2,4-Triazol-3-one antidepressants
IN158869B (ru) 1981-03-18 1987-02-07 Ici Plc
DD160447A1 (de) 1981-03-26 1983-08-03 Johannes Dost Herbizide mittel, die 1,2,4-triazolinone-(5) enthalten
DE3267110D1 (de) 1981-05-18 1985-12-05 Ici Plc Amidine derivatives
DE3238590A1 (de) 1982-10-19 1984-04-19 VEB Fahlberg-List Chemische und pharmazeutische Fabriken, DDR 3013 Magdeburg Herbizide mittel, die 1,2,4-triazolinone-(5) enthalten
NL8204109A (nl) 1982-10-25 1984-05-16 Fahlberg List Veb Herbicide middelen, die 1.2.4-triazolinon-(5)-verbindingen bevatten.
BE894856A (fr) 1982-10-28 1983-02-14 Fahlberg List Veb Compositions herbicides a base d'un derive de la 1,2,4-triazolinone-(5)
FR2535168B1 (fr) 1982-10-29 1985-08-09 Fahlberg List Veb Agents herbicides a base de 1, 2, 4-triazolinone 5
JPS60215675A (ja) 1984-04-09 1985-10-29 Nippon Nohyaku Co Ltd オキサジアゾリノン誘導体及びトリアゾリノン誘導体並びにその製造方法並びに昆虫成長制御剤
PH24094A (en) 1986-12-19 1990-03-05 Merrell Dow Pharma 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
DE3934081A1 (de) 1989-10-12 1991-04-18 Bayer Ag Sulfonylaminocarbonyltriazolinone
EP0500864B1 (en) 1990-09-06 2001-09-19 Pfizer Limited Antimuscarinic bronchodilators
JP2772875B2 (ja) 1991-05-14 1998-07-09 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料の処理方法及び写真用漂白定着組成物
EP0540318A1 (en) 1991-10-30 1993-05-05 Fisons Corporation 2-Heterocyclicethylamine derivatives and their use as pharmaceuticals
EP0636130A1 (en) 1992-04-15 1995-02-01 Merck Sharp & Dohme Ltd. Azacyclic compounds
DE4224929A1 (de) 1992-07-28 1994-02-03 Bayer Ag Heterocyclyltriazolinone
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
IT1256387B (it) 1992-11-13 1995-12-04 Acraf Procedimento per preparare triazoloni
US5783593A (en) 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
DE4343595A1 (de) 1993-12-21 1995-06-22 Bayer Ag Verfahren zur Herstellung von Sulfonylaminocarbonyltriazolinonen
US5550118A (en) 1994-01-31 1996-08-27 Eli Lilly And Company Polyhydronorharman synthase inhibitors
DE4404848A1 (de) 1994-02-16 1995-08-17 Hoechst Ag Substituierte Cyclohexanolester, ihre Verwendung zur Behandlung von Krankheiten und pharmazeutische Präparate
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
GB9418545D0 (en) 1994-09-15 1994-11-02 Merck Sharp & Dohme Therapeutic agents
JPH08157473A (ja) 1994-10-06 1996-06-18 Nissan Chem Ind Ltd ピラゾール系チアゾリジン類
US5641796A (en) 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
IN183333B (ru) 1995-03-15 1999-11-20 Indian Drugs & Pharma
IL118325A0 (en) 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
DE19521162A1 (de) 1995-06-09 1996-12-12 Bayer Ag N-Aryl-1,2,4-triazolin-5-one
GB9513117D0 (en) 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
GB9513121D0 (en) 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
DE19601189A1 (de) 1996-01-15 1997-07-17 Degussa Verfahren zur Herstellung von 1,2,4-Triazolin-3(2H)-onen
EP0784053A1 (de) 1996-01-15 1997-07-16 Degussa Aktiengesellschaft Verfahren zur Herstellung von Triazolinonherbiziden
AU2381397A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
TW467902B (en) 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
DE69736390T2 (de) 1996-10-07 2007-07-26 Merck Sharp & Dohme Ltd., Hoddesdon Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
ATE314097T1 (de) 1996-10-28 2006-01-15 Amersham Health As Kontrastmittel
US6214834B1 (en) 1997-03-28 2001-04-10 Dupont Pharmaceuticals Company Integrin inhibitor prodrugs
AU8242598A (en) 1997-07-18 1999-02-10 Nippon Kayaku Kabushiki Kaisha Aromatic ketone derivatives and uses thereof
CA2309204A1 (en) 1997-11-26 1999-06-03 Dupont Pharmaceuticals Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as .alpha.v.beta.3 antagonists
IL140040A0 (en) 1998-06-03 2002-02-10 Guilford Pharm Inc N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
HUP0102532A3 (en) 1998-06-03 2002-06-28 Gpi Nil Holdings Inc Wilmingto Aza-heterocyclic compounds used to treat neurological disorders and hair loss and process for their preparation and pharmaceutical compositions containing them
CA2336152A1 (en) 1998-08-14 2000-02-24 Gpi Nil Holdings, Inc. Ureas and carbamates of n-heterocyclic carboxylic acids and isosteres for vision and memory disorders
US7265150B1 (en) 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
SE9802937D0 (sv) * 1998-09-01 1998-09-01 Astra Pharma Prod Novel compounds
WO2000029386A1 (en) 1998-11-12 2000-05-25 Merck & Co., Inc. Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists
FR2793791B1 (fr) 1999-05-19 2002-01-25 Univ Paris 7 Denis Diderot Nouveaux composes inhibiteurs specifiques de phospholipases a2
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
DE19955662B4 (de) 1999-11-19 2011-03-31 Arysta LifeScience North America, Herbizide auf Basis von Carbamoyltriazolinon
EP1110958A1 (en) 1999-12-20 2001-06-27 Ucb, S.A. Alpha-arylethylpiperazine derivatives as neurokinin antagonists
AU6594401A (en) 2000-05-24 2001-12-03 Bayer Aktiengesellschaft 6-heterocyclyl-3-oxo-3,4-dihydro-quinoxalines
US6465456B2 (en) 2000-06-29 2002-10-15 Bristol-Myers Squibb Company Isoxazolinone antibacterial agents
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
UA82048C2 (ru) 2000-11-10 2008-03-11 Эли Лилли Энд Компани Агонисты альфа-рецепторов, активированных пролифератором пероксисом
WO2003000682A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
DE60222698T2 (de) 2001-12-18 2008-06-19 Merck & Co., Inc. Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5
AU2003210916B9 (en) 2002-02-07 2008-12-18 The Curators Of The University Of Missouri Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
US20050256003A1 (en) 2002-06-14 2005-11-17 Christoph Luthy Novel herbicides
AU2003284001A1 (en) * 2002-10-07 2004-05-04 Bristol-Myers Squibb Company Triazolone and triazolethione derivatives
BR0315247A (pt) 2002-10-11 2005-08-30 Cytokinetics Inc Composição, composição farmacêutica, método de tratamento para uma doença proliferativa celular, e, kit
AU2003300031A1 (en) 2002-10-11 2004-05-04 Cytokinetics, Inc. Compounds, compositions, and methods
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
EP1613617A4 (en) 2003-04-04 2009-02-18 Merck & Co Inc METABOTROPIC GLUTAMATE RECEPTOR-5 DIARYLSUBSTITUTED TRIAZOLE MODULATORS
EP1615647B1 (en) 2003-04-11 2010-01-20 High Point Pharmaceuticals, LLC Pharmaceutical use of fused 1,2,4-triazoles
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
EP1697333A4 (en) 2003-12-17 2009-07-08 Merck & Co Inc (3,4-DISUBSTITUTED) PROPANE ACID BOXYLATES AS AGONISTS OF THE S1P (EDG) RECEPTOR
WO2005077345A1 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
WO2005077178A2 (en) 2004-02-16 2005-08-25 Syngenta Participations Ag Herbicidal composition
RU2006127575A (ru) 2004-02-18 2008-03-27 Астразенека Аб (Se) Соединение триазола и их применение в качестве антагонистов метаботропного рецептора глутамата
SE0400850D0 (sv) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
BRPI0513858B8 (pt) 2004-07-27 2021-05-25 Hoffmann La Roche compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende
CN1315810C (zh) 2004-08-30 2007-05-16 北京理工大学 哌嗪桥联他克林双体衍生物及其合成方法
GT200500284A (es) 2004-10-15 2006-03-27 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
CA2583681A1 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
WO2006068199A1 (ja) 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体
WO2006074984A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Pyrazolopyrimidines as cell cycle kinase inhibitors
WO2006078698A1 (en) 2005-01-19 2006-07-27 Cengent Therapeutics, Inc. 2-imidazolone and 2-imidazolidinone heterocyclic inhibitors of tyrosine phosphatases
DOP2006000018A (es) 2005-01-28 2006-07-15 Lilly Co Eli Formulaciones y regimen de dosificación para moduladores alfa de ppar
WO2006109056A1 (en) 2005-04-12 2006-10-19 Vicore Pharma Ab New tricyclic angiotensin ii agonists
KR101082929B1 (ko) 2005-04-28 2011-11-11 가부시키가이샤 덴소 Ac 모터
DE102005025992A1 (de) 2005-06-07 2007-01-11 Lanxess Deutschland Gmbh Verfahren zur Herstellung von substituierten Azolen
WO2007019397A2 (en) 2005-08-05 2007-02-15 Genelabs Technologies, Inc. 6-membered aryl and heteroaryl derivatives for the treatment of hepatitis c virus
CA2627497C (en) 2005-10-28 2014-10-14 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
KR20080080584A (ko) 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 ｃ-Ｍｅｔ의 억제제 및 이의 용도
DE102006003444A1 (de) 2006-01-25 2007-07-26 Lanxess Deutschland Gmbh Verfahren zur Herstellung von iodierten Azolen
GB2435828A (en) 2006-03-09 2007-09-12 Del Dr Esteve S A Spain Lab Use of substituted phenyl-piperazine compounds for treatment of food related disorders
GB2435829A (en) 2006-03-09 2007-09-12 Del Dr Esteve S A Spain Lab Pyrimidinyl-2-piperazine compounds for use in disorders related to food intake
GB2435827A (en) 2006-03-09 2007-09-12 Del Dr Esteve S A Spain Lab Use of substituted piperazine compounds for the treatment of food related disorders
EP1834953A1 (en) 2006-03-14 2007-09-19 Ranbaxy Laboratories Limited Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors
WO2007107758A1 (en) 2006-03-23 2007-09-27 Prolysis Ltd Antibacterial agents
NZ571441A (en) 2006-03-24 2010-08-27 Eisai R&D Man Co Ltd Triazolone derivative
DE102006023337A1 (de) 2006-05-18 2007-11-22 Merck Patent Gmbh Triazolderivate II
WO2007139955A2 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
DE102006032164A1 (de) 2006-07-12 2008-01-24 Bayer Cropscience Ag Substituierte Furyl-sulfonylamino(thio)carbonyl-triazolin(thi)one
US7994321B2 (en) 2006-08-08 2011-08-09 Hoffmann-La Roche Inc. Substituted thieno[3,2-C]pyridine-7-carboxylic acid derivatives
MX2009001634A (es) 2006-08-15 2009-02-25 Novartis Ag Compuestos heterociclicos adecuados para el tratamiento de enfermedades relacionadas con el nivel elevado de lipidos.
EA200970793A1 (ru) 2007-02-23 2010-02-26 Эли Лилли Энд Компани Модуляторы рецепторов, активируемых пролифераторами пероксисом
WO2008119662A1 (en) 2007-03-29 2008-10-09 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
WO2008128335A1 (en) 2007-04-20 2008-10-30 Merck Frosst Canada Ltd. Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
CA2685962A1 (en) 2007-05-08 2009-02-05 Burnham Institute For Medical Research Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
US8252822B2 (en) 2007-07-17 2012-08-28 Acea Biosciences, Inc. Heterocyclic compounds and uses as anticancer agents
AU2008279447A1 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
JP5358571B2 (ja) 2007-08-07 2013-12-04 プロサリク リミテッド セロトニン作動性調節因子としての１，２，４−トリアゾール誘導体
EP2215065B1 (en) 2007-10-19 2012-07-11 Boehringer Ingelheim International GmbH Ccr10 antagonists
EP2231615A1 (en) 2007-12-10 2010-09-29 7TM Pharma A/S Cannabinoid receptor modulators
US20090281089A1 (en) 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
EP3782991A1 (en) 2008-05-14 2021-02-24 The Scripps Research Institute Novel modulators of sphingosine phosphate receptors
US8461183B2 (en) 2008-05-26 2013-06-11 Genfit PPAR agonist compounds, preparation and uses
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
US7943796B2 (en) * 2008-07-31 2011-05-17 Chevron Oronise Company LLC Lubricating oil additive and lubricating oil composition containing same
CN101643451B (zh) 2008-08-07 2013-03-06 浙江海正药业股份有限公司 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
JP2011231015A (ja) 2008-08-29 2011-11-17 Taiho Yakuhin Kogyo Kk 含窒素複素環を有する新規ウラシル化合物又はその塩
EA022417B1 (ru) 2008-10-21 2015-12-30 Саймабэй Терапевтикс, Инк. Арильные агонисты рецептора gpr120 и их применение
KR101220182B1 (ko) 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
CA2764339A1 (en) 2009-06-05 2010-12-09 Oslo University Hospital Hf Azole derivatives as wtn pathway inhibitors
WO2011005595A2 (en) 2009-06-24 2011-01-13 Alios Biopharma, Inc. 2-5a analogs and their methods of use
DE102009028929A1 (de) 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
WO2011058478A1 (en) 2009-11-16 2011-05-19 Pfizer Inc. Substituted triazolopyrimidines as pde8 inhibitors
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
KR101169359B1 (ko) 2010-01-29 2012-07-30 주식회사 레고켐 바이오사이언스 사이클릭 아미드라존 기를 가지는 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물
ES2509951T3 (es) 2010-02-22 2014-10-20 Glaxosmithkline Llc Triazolonas como inhibidores de sintasa de ácidos grasos
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
CN102918034B (zh) 2010-03-30 2015-06-03 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
EP2371823A1 (de) 2010-04-01 2011-10-05 Bayer CropScience AG Cyclopropyl-substituierte Phenylsulfonylamino(thio)carbonyltriazolinone, ihre Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
US8097634B2 (en) 2010-04-15 2012-01-17 Hoffmann-La Roche Inc. Azacyclic derivatives
RS60310B1 (sr) 2010-08-10 2020-07-31 Rempex Pharmaceuticals Inc Ciklični derivati estra boronske kiseline, postupak za pripremu injihove terapeutske upotrebe
US20130158063A1 (en) 2010-08-24 2013-06-20 Georgetown University Compounds, Compositions and Methods Related to PPAR Antagonists
JP2014508097A (ja) * 2010-09-17 2014-04-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 脂肪酸合成酵素阻害剤
JP5847533B2 (ja) 2010-10-19 2016-01-27 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
WO2012058531A2 (en) 2010-10-29 2012-05-03 North Carolina State University Modulation of response regulators by imidazole derivatives
EP2822931B1 (en) 2012-03-09 2017-05-03 Inception 2, Inc. Triazolone compounds and uses thereof
SG11201504622PA (en) 2012-12-20 2015-07-30 Inception 2 Inc Triazolone compounds and uses thereof
CN105579440A (zh) 2013-09-06 2016-05-11 因森普深2公司 三唑酮化合物及其应用

Also Published As

Publication number Publication date
IL239372B (en) 2018-08-30
EA201590909A1 (ru) 2015-12-30
HK1212680A1 (zh) 2016-06-17
US20240041837A1 (en) 2024-02-08
US20150344446A1 (en) 2015-12-03
WO2014099503A1 (en) 2014-06-26
JP2016508132A (ja) 2016-03-17
MX376108B (es) 2025-03-07
JP6404230B2 (ja) 2018-10-10
EP2935228B1 (en) 2017-08-02
EP2935228A4 (en) 2016-05-04
EA027986B1 (ru) 2017-09-29
BR112015013350B1 (pt) 2022-04-05
US11666557B2 (en) 2023-06-06
PE20151521A1 (es) 2015-11-25
KR102300675B1 (ko) 2021-09-13
US10568871B2 (en) 2020-02-25
CA2894281C (en) 2021-04-20
US20170239223A1 (en) 2017-08-24
ES2660249T3 (es) 2018-03-21
DK2935228T3 (en) 2017-10-30
CN104918922B (zh) 2017-04-26
BR112015013350A2 (pt) 2017-07-11
CA2894281A1 (en) 2014-06-26
AU2013363398A1 (en) 2015-07-23
KR20150099537A (ko) 2015-08-31
US20200138790A1 (en) 2020-05-07
US9676754B2 (en) 2017-06-13
EP2935228A1 (en) 2015-10-28
MX2015007433A (es) 2015-12-07
EP2935228B9 (en) 2017-12-06
SG11201504622PA (en) 2015-07-30
NO3003327T3 (ru) 2018-01-06
IL239372A0 (en) 2015-07-30
CN104918922A (zh) 2015-09-16
AU2013363398B2 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
MX2016002795A (es) Compuestos de triazolona y usos de los mismos.
CY1124882T1 (el) Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn
NZ722345A (en) Pyrazolone compounds and uses thereof
CY1124793T1 (el) Ακρυλαμιδια πυρρολο[2,3-d]πυριμιδινυλιου, πυρρολo[2,3-β]πυραζινυλιου και πυρρολο[2,3-d]πυριδινυλιου
MD4800B1 (ru) Соединения аминопиримидинила в качестве ингибиторов JAK
JOP20180009A1 (ar) مركبات مثبط فيروس hiv
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
TR201906470T4 (tr) İmmünomodülatörler.
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
MY196749A (en) Eif4a-inhibiting compounds and methods related thereto
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
PH12015501517A1 (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
BR112012027743A2 (pt) ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas
NZ611866A (en) Spiro-oxindole mdm2 antagonists
MD20140136A2 (ru) Ингибиторы вируса гепатита С
MX368703B (es) Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer.
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
EA201591301A1 (ru) Новые пиримидиновые и пиридиновые соединения и их применение
EA027986B9 (ru) Соединения триазолона и их применение
IN2015DN01119A (ru)
EA201591024A1 (ru) Димерные соединения
MX2015010619A (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer.
EA201591177A1 (ru) Трициклические соединения для ингибирования канала cftr
MX2015008288A (es) Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
TC4A Change in name of a patent proprietor in a eurasian patent